Abstract: The development of obesity is still increasing worldwide. Likewise, metabolic syndrome, which is a collection of obesity-associated disorders, is associated with development of cardiovascular diseases, insulin resistance, hepatic steatosis, certain types of cancer and type 2 diabetes. Recently, seven peptides were isolated from F.prausnitzii and were shown as deriving from a single Microbial Anti-inflammatory Molecule (MAM). The inventors shows that L-MAM treatment prevented animals from development of High-Fat Diet-induced obesity. L-MAM treated mice significantly gained less weight throughout the gavage as compared to HFD-fed control experiment. The difference in body weight between L-MAM-treated animals on a HFD and the remaining animals is largely due to a significant reduction in the percentage of fat mass and a significant increase in the percentage of lean mass. Oral glucose tolerance testing (OGTT) revealed that chronic administration of L-MAM increased glucose tolerance.

Abstract: The present invention relates to a bacterial of the Streptococcus thermophilus species with reference CNRZ160, for use in the prevention and/or treatment of intestinal inflammation in an individual.

Abstract: A method for preventing or treating an inflammatory disease, such as inflammatory bowel disease and Crohn disease, is presented. The method includes administering to a patient a polypeptide having the amino acid sequence of SEQ ID NO: 1, a conservative derivative or a fragment thereof, a nucleic acid sequence encoding said polypeptide, a vector comprising said nucleic acid sequence or a host cell that has been transfected, infected or transformed by said nucleic acid sequence and/or by said vector.

Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.

Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.

Abstract: A method for preventing or treating an inflammatory disease, such as inflammatory bowel disease and Crohn disease, is presented. The method includes administering to a patient a polypeptide having the amino acid sequence of SEQ ID NO: 1, a conservative derivative or a fragment thereof, a nucleic acid sequence encoding said polypeptide, a vector comprising said nucleic acid sequence or a host cell that has been transfected, infected or transformed by said nucleic acid sequence and/or by said vector.

Abstract: A polypeptide including or consisting of the amino acid sequence SEQ ID NO: 1, for use in the treatment or prevention of an inflammatory disease. A nucleic acid sequence encoding the polypeptide, a vector including the nucleic acid and a host cell including the nucleic acid sequence and/or a vector, for use in the treatment or prevention of an inflammatory disease are also described. A pharmaceutical composition including the polypeptide, the nucleic acid sequence, the vector or the host cell and a pharmaceutically acceptable carrier, for the treatment of inflammatory disease are also disclosed.